Drugs / Revacept
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01042964 | Mar 2006 → Jan 2007 | acute coronary syndrome, myocardial infarction, stroke disorder, thrombotic disease | AdvanceCor GmbH | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03312855 | Nov 2017 → Feb 2020 | coronary artery disorder | German Heart Center Munich | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01645306 Comparator | Mar 2013 → Oct 2018 | amaurosis fugax, atherosclerosis, carotid stenosis, transient ischemic attack | AdvanceCor GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | revacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01042964 ↗ |
| Known as | PR-15 | “single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.” NCT01042964 ↗ |
| Action | Inhibit | “Revacept, a competitive antagonist of glycoprotein VI, adjunct to standard antiplatelet therapy reduces the occurrence of ischemic lesions in patients with symptomatic ICA stenosis.” PMID 35695006 ↗ Jun 2022 |
| Modality | Protein / enzyme biologic | “Revacept is a protein” NCT03312855 ↗ |
| Route | Intravenous | “single intravenous administration” NCT01042964 ↗ |